NCT00982397

Brief Summary

The purpose of the study is two-fold. In Phase I (Protecta Clinical Study), system performance will be evaluated. In Phase II (PainFree SST), the inappropriate shock-free rate at one year of subjects implanted with a Medtronic Protecta implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) will be evaluated.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
2,770

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2009

Longer than P75 for not_applicable

Geographic Reach
21 countries

122 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2009

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

September 22, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 23, 2009

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2013

Completed
4.2 years until next milestone

Results Posted

Study results publicly available

November 6, 2017

Completed
Last Updated

November 6, 2017

Status Verified

October 1, 2017

Enrollment Period

4 years

First QC Date

September 22, 2009

Results QC Date

May 25, 2016

Last Update Submit

October 5, 2017

Conditions

Outcome Measures

Primary Outcomes (3)

  • Percentage of Subjects Who Are Inappropriate Shock Free

    Primary objective of Phase II. Subjects implanted with a VR device will be analyzed separately from subjects implanted with a DR / CRT-D device. An inappropriate shock is a shock delivered by the defibrillator when the patient's heart rhythm was not a tachyarrhythmia, as adjudicated by the independent Episode Review Committee .

    Implant to one year post-implant

  • Percentage of Subjects With Unanticipated Severe Adverse Device Effects (Phase I)

    In Phase I, only DR-ICD/CRT-D devices were implanted, so that for Phase I objectives there is only 1 arm to report results for.

    Implant to one month post-implant

  • Percentage of Phase I Subjects Where the Ventricular Fibrillation (VF) Detection Time With Protecta Features on is no More Than 2 Seconds Longer Than the VF Detection Time With Protecta Features Off

    In Phase I, only DR-ICD/CRT-D devices were implanted, so that for Phase I objectives there is only 1 arm to report results for.

    At implant

Secondary Outcomes (1)

  • Percentage of Secondary Prevention Subjects Who Are Syncopal Event Free

    Implant to one year post-implant

Study Arms (2)

Single-chamber detetction

EXPERIMENTAL

Patients implanted with a Protecta VR-ICD.

Device: Protecta VR-ICD

Dual-chamber detection

EXPERIMENTAL

Patients implanted with a Protecta DR-ICD or CRT-D.

Device: Protecta DR-ICD or CRT-D

Interventions

Protecta single-chamber implantable cardioverter defibrillators.

Single-chamber detetction

Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.

Dual-chamber detection

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients meeting one of the following criteria can be included in Phase I of the study:
  • Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D)
  • Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant)
  • Patients meeting one of the following criteria can be included in Phase II of the study:
  • Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device
  • Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D
  • Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant

You may not qualify if:

  • Patients with a mechanical tricuspid heart valve
  • Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study
  • Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients
  • Patients anticipated not being able to complete the study
  • Patients unwilling to provide written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (122)

Birmingham Heart Clinic PC

Birmingham, Alabama, 35235, United States

Location

CardioVasular Associates of Mesa

Mesa, Arizona, 85206, United States

Location

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903, United States

Location

LA Cardiology Associates

Los Angeles, California, 90017, United States

Location

Cardiology Consultants of Napa Valley

Napa, California, 94558, United States

Location

Hartford Hospital

Hartford, Connecticut, 06102, United States

Location

University of Florida Health at Jacksonville

Jacksonville, Florida, 32209, United States

Location

Arrhythmia Syncope Consultants LLC

Miami, Florida, 33133, United States

Location

Indiana Heart Physicians

Indianapolis, Indiana, 46237, United States

Location

Cardiovascular Research of Northwest Indiana

Munster, Indiana, 46321, United States

Location

Iowa Heart Center

West Des Moines, Iowa, 50314, United States

Location

Delmarva Heart Research Foundation

Salisbury, Maryland, 21804, United States

Location

Essentia Institute of Rural Health

Duluth, Minnesota, 55805, United States

Location

CentraCare Heart & Vascular Center

Saint Cloud, Minnesota, 56303, United States

Location

Saint John's Medical Research Inc

Springfield, Missouri, 65804, United States

Location

Saint Louis Heart & Vascular PC

St Louis, Missouri, 62040, United States

Location

Cardiology PC

Syracuse, New York, 13210, United States

Location

Pinehurst Medical Clinic

Pinehurst, North Carolina, 28374, United States

Location

Ohio Heart and Vascular

Cincinnati, Ohio, 45219, United States

Location

St. Vincent Mercy Medical Center

Toledo, Ohio, 43608, United States

Location

Central Bucks Cardiology

Doylestown, Pennsylvania, 18901, United States

Location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Pee Dee Cardiology

Florence, South Carolina, 29506, United States

Location

Cardiology Consultants PA

Spartanburg, South Carolina, 29303, United States

Location

Centennial Heart Cardiovascular Consultants LLC

Nashville, Tennessee, 37203, United States

Location

Hall-Garcia Cardiology Associates

Houston, Texas, 77030, United States

Location

Virginia Commonwealth University Health System

Richmond, Virginia, 23298, United States

Location

Spokane Cardiology

Spokane, Washington, 99204, United States

Location

Columbia St. Mary's Hospital

Milwaukee, Wisconsin, 53211, United States

Location

LKH - Universitätsklinikum Graz

Graz, Austria

Location

Landesklinikum St. Pölten

Sankt Pölten, Austria

Location

Klinikum Wels-Grieskirchen GmbH

Wels, Austria

Location

Saint Paul's Hospital (Vancouver BC)

Vancouver, British Columbia, Canada

Location

Royal Jubilee Hospital

Victoria, British Columbia, Canada

Location

Institut Universitaire de Cardiologieet de Pneumologie de Québec (IUCPQ)

Halifax, Nova Scotia, Canada

Location

Newmarket Electrophysiology Research Group

Newmarket, Ontario, Canada

Location

Queen Elizabeth II Health Sciences Centre

Halifax, Canada

Location

Kelowna Arrhythmia Research

Kelowna, Canada

Location

Queen's University & Kingston General Hospital

Kingston, Canada

Location

London Health Sciences Centre - University Campus

London, Canada

Location

Montreal Heart Institute

Montreal, Canada

Location

University of Ottawa Heart Institute

Ottawa, Canada

Location

Fundacion Cardioinfantil

Bogotá, Colombia

Location

Hospital Cardiovascular del Nino

Bogotá, Colombia

Location

Clinica Cardiovascular Santa Maria

Medellín, Colombia

Location

Krajska nemocnice Liberec a.s. - Kardiocentrum

Liberec, Czechia

Location

Aalborg Sygehus

Aalborg, Denmark

Location

Aarhus Universitetshospital - Skejby

Aarhus, Denmark

Location

Herz- und Gefässzentrum Bad Bevensen

Bad Bevensen, Germany

Location

Herz- und Diabeteszentrum NRW - Ruhr-Universität Bochum

Bad Oeynhausen, Germany

Location

Segeberger Kliniken GmbH

Bad Segeberg, Germany

Location

Berufsgenossenschaftliche Universitätsklinik Bergmannsheil GmbH

Bochum, Germany

Location

Universitätsklinikum Bonn

Bonn, Germany

Location

MVZ am Küchwald GmbH ambulantes Herz Zentrum Chemnitz

Chemnitz, Germany

Location

Klinikum Coburg GmbH

Coburg, Germany

Location

Kardiocentrum Frankfurt an der Klinik Rotes Kreuz

Frankfurt, Germany

Location

Universitätsmedizin Göttingen Georg-August-Universität

Göttingen, Germany

Location

Ruprecht-Karls-Universität

Heidelberg, Germany

Location

Westpfalz-Klinikum GmbH - Standort I Kaiserslautern

Kaiserslautern, Germany

Location

Herz Zentrum Bodensee

Konstanz, Germany

Location

Klinikum Ludwigsburg - Akademisches Lehrkrankenhaus der Universität Heidelberg

Ludwigsburg, Germany

Location

Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Mainz, Germany

Location

Städtische Kliniken München GmbH - Klinikum Bogenhausen

München, Germany

Location

Städtische Kliniken Neuss Lukaskrankenhaus GmbH-Akad.Lehrkrankenhaus d. Heinrich-Heine-Universität

Neuss, Germany

Location

Universitätsmedizin Rostock

Rostock, Germany

Location

Herz- und Kreislaufzentrum Rotenburg a.d. Fulda GmbH

Rotenburg A.d. Fulda, Germany

Location

Asklepios Kliniken Schwalm - Eder GmbH - Klinikum Schwalmstadt

Schwalmstadt, Germany

Location

Heinrich-Braun-Klinikum Zwickau gemeinnützige GmbH

Zwickau, Germany

Location

Care Institute of Medical Sciences

Ahmedabad, India

Location

Medanta-The Medicity

Gūrgaon, India

Location

Barzilai Medical Center Ashkelon

Ashkelon, Israel

Location

Soroka University Medical Center

Be'er Sheba, Israel

Location

Carmel Medical Center

Haifa, Israel

Location

Rambam Health Care Campus

Haifa, Israel

Location

Shaare Zedek Medical Center

Jerusalem, Israel

Location

Rabin Medical Center - Beilinson Hospital

Petah Tikva, Israel

Location

Chaim Sheba Medical Center

Ramat Gan, Israel

Location

Kaplan Medical Center

Rehovot, Israel

Location

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Location

Ospedale classificato ed equiparato Sacro Cuore - Don Calabria

Negrar, Italy

Location

Azienda Complesso Ospedaliero San Filippo Neri - Ospedale San Filippo Neri

Rome, Italy

Location

Hirosaki University School of Medicine & Hospital

Hirosaki, Aomori, Japan

Location

Kansai Rosai Hospital

Amagasak, Hyōgo, Japan

Location

Kobe University Hospital

Kobe, Hyōgo, Japan

Location

St. Marianna University School of Medicine Hospital

Kawasaki, Kanagawa, Japan

Location

Kinki University Hospital

Osakasaya, Osaka, Japan

Location

National Cerebral and Cardiovasuclar Center

Suita, Osaka, Japan

Location

Sapporo Medical Center NTT EC

Chūōku, Sapporo, Japan

Location

Akita Medical Center

Akita, Japan

Location

Chiba University Hospital

Chiba, Japan

Location

Kokura Memorial Hospital

Kitakyushu, Japan

Location

Kumamoto University Hospital

Kumamoto, Japan

Location

Kyoto University Hospital

Kyoto, Japan

Location

Niigata University Medical & Dental Hospital

Niigata, Japan

Location

Kitasato University Hospital

Sagamihara, Japan

Location

Institut Jantung Negara - National Heart Institute

Kuala Lumpur, Malaysia

Location

Medisch Centrum Alkmaar

Alkmaar, Netherlands

Location

Academisch Medisch Centrum (AMC)

Amsterdam, Netherlands

Location

Amphia Ziekenhuis - Locatie Molengracht Breda

Breda, Netherlands

Location

Catharina Ziekenhuis

Eindhoven, Netherlands

Location

Medisch Spectrum Twente

Enschede, Netherlands

Location

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands

Location

Leids Universitair Medisch Centrum

Leiden, Netherlands

Location

St. Antonius Ziekenhuis

Nieuwegein, Netherlands

Location

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands

Location

King Faisal Specialist Hospital & Research Center

Riyadh, Saudi Arabia

Location

Prince Salman Heart Centre - King Fahad Medical City

Riyadh, Saudi Arabia

Location

University Medical Centre Ljubljana

Ljubljana, Slovenia

Location

Milpark Hospital

Johannesburg, South Africa

Location

Hospital De Cruces

Barakaldo, Spain

Location

Hospital Universitario 12 de Octubre

Madrid, Spain

Location

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Spain

Location

Complejo Hospitalario Universitario de Vigo (CHUVI) - Hospital del Meixoeiro

Vigo, Spain

Location

Universitetssjukhuset i Lund

Lund, Sweden

Location

Universitetssjukhuset Örebro

Örebro, Sweden

Location

Capio S:t Görans Sjukhus

Stockholm, Sweden

Location

Cardio Centro Ticino

Lugano, Switzerland

Location

Sheikh Khalifa Medical Center

Abu Dhabi, United Arab Emirates

Location

Royal Bournemouth Hospital

Bournemouth, United Kingdom

Location

Liverpool Heart and Chest Hospital NHS Foundation Trust

Liverpool, United Kingdom

Location

King's College Hospital NHS Foundation Trust

London, United Kingdom

Location

Southampton General Hospital - University Hospital Southampton NHS Foundation Trust

Southampton, United Kingdom

Location

Related Publications (6)

  • Auricchio A, Meijer A, Kurita T, Schloss E, Brinkman K, Claessens-van Ooijen M, Sterns L. Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design. Europace. 2011 Oct;13(10):1484-93. doi: 10.1093/europace/eur133. Epub 2011 Jun 13.

    PMID: 21669960BACKGROUND
  • Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, AlSmadi FM, Leng CT, Sterns LD; PainFree SST Investigators. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. 2015 May;12(5):926-36. doi: 10.1016/j.hrthm.2015.01.017. Epub 2015 Jan 28.

  • Sterns LD, Meine M, Kurita T, Meijer A, Auricchio A, Ando K, Leng CT, Okumura K, Sapp JL, Brown ML, Lexcen DR, Gerritse B, Schloss EJ. Extended detection time to reduce shocks is safe in secondary prevention patients: The secondary prevention substudy of PainFree SST. Heart Rhythm. 2016 Jul;13(7):1489-96. doi: 10.1016/j.hrthm.2016.03.022. Epub 2016 Mar 14.

  • Wollmann CG, Lawo T, Kuhlkamp V, Becker R, Garutti C, Jackson T, Brown ML, Mayr H. Implantable defibrillators with enhanced detection algorithms: detection performance and safety results from the PainFree SST study. Pacing Clin Electrophysiol. 2014 Sep;37(9):1198-209. doi: 10.1111/pace.12390. Epub 2014 Mar 25.

  • Zweibel S, Cronin EM, Schloss EJ, Auricchio A, Kurita T, Sterns LD, Gerritse B, Lexcen DR, Cheng A. Estimating the incidence of atrial fibrillation in single-chamber implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol. 2019 Feb;42(2):132-138. doi: 10.1111/pace.13555. Epub 2018 Dec 13.

  • Kurita T, Ando K, Ueda M, Shizuta S, Okamura H, Matsumoto N, Gerritse B, Fagan DH, Schloss EJ, Meijer A, Auricchio A, Sterns LD, Okumura K; PainFree SST investigators. Comparison of ICD shock rates in Japanese and non-Japanese patients in the PainFree SST study. Pacing Clin Electrophysiol. 2018 Sep;41(9):1185-1191. doi: 10.1111/pace.13427. Epub 2018 Aug 13.

MeSH Terms

Conditions

TachycardiaHeart FailureVentricular Dysfunction

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
CRHF Clinical Research
Organization
Medtronic, plc

Study Officials

  • A. Meijer, Dr.

    Eindhoven, The Netherlands

    PRINCIPAL INVESTIGATOR
  • A. Auricchio, Prof.

    Lugano, Switzerland

    PRINCIPAL INVESTIGATOR
  • T. Kurita, Dr.

    Higashi-Osaka, Japan

    PRINCIPAL INVESTIGATOR
  • E.J. Schloss, Dr.

    Cincinnati Ohio, USA

    PRINCIPAL INVESTIGATOR
  • L. Sterns, Dr.

    Victoria, British Columbia, Canada

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 22, 2009

First Posted

September 23, 2009

Study Start

September 1, 2009

Primary Completion

September 1, 2013

Study Completion

September 1, 2013

Last Updated

November 6, 2017

Results First Posted

November 6, 2017

Record last verified: 2017-10

Data Sharing

IPD Sharing
Will not share

Locations